Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma

Yao,Min; Wang,Xiaomei; Zhao,Yufeng; Wang,Xiaomeng; Gao,Feng

doi:10.3892/mmr.2016.6077

Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma

Authors:
- Min Yao
- Xiaomei Wang
- Yufeng Zhao
- Xiaomeng Wang
- Feng Gao
View Affiliations

Affiliations: Department of Pathology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: December 27, 2016 https://doi.org/10.3892/mmr.2016.6077
Pages: 915-921

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) serve an important role in chondrosarcoma. The present study investigated whether the expression of MMPs was dependent on the activity of mitogen-activated protein kinase (MAPK) in chondrosarcoma. Surgical pathological specimens were collected to detect MMP-1, MMP-13, TIMP-1, type II collagen and phosphorylated MAPK levels in normal cartilage, enchondroma and chondrosarcoma tissues. The expression of MMP‑1, MMP‑13, TIMP‑1 and type II collagen was investigated utilizing MAPK inhibitors in chondrosarcoma cells. It was noted that the expression levels of MMP‑1, MMP‑13 and TIMP‑1 were increased in chondrosarcoma with the activity of MAPK. After chondrosarcoma cells were pretreated with MAPK inhibitors, the levels of MMP‑1, MMP‑13 and TIMP‑1 were inhibited. Furthermore, MMP‑1 and MMP‑13 are essential in regulating the degradation of type II collagen and decomposing cartilage matrix major. The high expression levels of MMP‑1 and MMP‑13 in chondrosarcoma expedite the invasion by chondrosarcoma cells and their expression can be depressed by MAPK inhibitors.

View Figures

View References

1	Leddy LR and Holmes RE: Chondrosarcoma of bone. Cancer Treat Res. 162:117–130. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH and Bovée JV: The clinical approach towards chondrosarcoma. Oncologist. 13:320–329. 2008. View Article : Google Scholar : PubMed/NCBI
3	Van Gompel JJ and Janus JR: Chordoma and chondrosarcoma. Otolaryngol Clin North Am. 48:501–514. 2015. View Article : Google Scholar : PubMed/NCBI
4	Yuan J, Dutton CM and Scully SP: RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res. 32:1467–1474. 2005. View Article : Google Scholar
5	Sakimura R, Tanaka K, Yamamoto S, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Li Y and Iwamoto Y: The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res. 13:275–282. 2007. View Article : Google Scholar : PubMed/NCBI
6	Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, Shiomi T, Okada Y, Itoh T, Itohara S, et al: Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res. 67:4311–4319. 2007. View Article : Google Scholar : PubMed/NCBI
7	Park JM, Kim A, Oh JH and Chung AS: Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis. 28:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chiu YC, Yang RS, Hsieh KH, Fong YC, Way TD, Lee TS, Wu HC, Fu WM and Tang CH: Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol Pharmacol. 72:695–703. 2007. View Article : Google Scholar : PubMed/NCBI
9	Brown GT and Murray GI: Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 237:273–281. 2015. View Article : Google Scholar : PubMed/NCBI
10	Moon JW, Choi JH, Lee SK, Lee YW, Lee JO, Kim N, Lee HJ, Seo JS, Kim J, Kim HS, et al: Promoter hypermethylation of membrane type 3 matrix metalloproteinase is associated with cell migration in colorectal adenocarcinoma. Cancer Genet. 208:261–270. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang X, Yin P, DI D, Luo G, Zheng L, Wei J, Zhang J, Shi Y, Zhang J and Xu N: IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res. 29:4497–4501. 2009.PubMed/NCBI
12	Galoian KA, Garamszegi N, Garamszegi SP and Scully SP: Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential. Exp Biol Med (Maywood). 232:515–522. 2007.PubMed/NCBI
13	Pritchard AL and Hayward NK: Molecular pathways: Mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res. 19:2301–2309. 2013. View Article : Google Scholar : PubMed/NCBI
14	Klein AM, Zaganjor E and Cobb MH: Chromatin-tethered MAPKs. Curr Opin Cell Biol. 25:272–277. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chen PN, Hsieh YS, Chiou HL and Chu SC: Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 156:141–150. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP and Atabey N: Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 7:e427172012. View Article : Google Scholar : PubMed/NCBI
17	Lin CW, Hou WC, Shen SC, Juan SH, Ko CH, Wang LM and Chen YC: Quercetin inhibition of tumor invasion via suppressing PKC/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis. 29:1807–1815. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zhao HJ, Liu T, Mao X, Han SX, Liang RX, Hui LQ, Cao CY, You Y and Zhang LZ: Fructus phyllanthi tannin fraction induces apoptosis and inhibits migration and invasion of human lung squamous carcinoma cells in vitro via MAPK/MMP pathways. Acta Pharmacol Sin. 36:758–768. 2015. View Article : Google Scholar : PubMed/NCBI
19	Cohen M, Meisser A, Haenggeli L and Bischof P: Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. Mol Hum Reprod. 12:225–232. 2006. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative pcr and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Iwamoto Y: Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol. 37:79–89. 2007. View Article : Google Scholar : PubMed/NCBI
22	Tan TW, Yang WH, Lin YT, Hsu SF, Li TM, Kao ST, Chen WC, Fong YC and Tang CH: Cyr61 increases migration and MMP-13 expression via alphavbeta3 integrin, FAK, ERK and AP-1-dependent pathway in human chondrosarcoma cells. Carcinogenesis. 30:258–268. 2009. View Article : Google Scholar : PubMed/NCBI
23	Tarín C, Gomez M, Calvo E, López JA and Zaragoza C: Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: A role in atherosclerosis. Arterioscler Thromb Vasc Biol. 29:27–32. 2009. View Article : Google Scholar : PubMed/NCBI
24	Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A and Quaranta M: Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 30:3521–3527. 2010.PubMed/NCBI
25	Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T and Santala M: Matrix metalloproteinase-2 (MMP-2) and −9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res. 27:2753–2758. 2007.PubMed/NCBI
26	Roomi MW, Kalinovsky T, Niedzwiecki A and Rath M: Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines. Int J Oncol. 47:370–376. 2015.PubMed/NCBI
27	Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N and Kirimlioğlu V: The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: Role of matrix metalloproteinases in tumor progression and prognosis. Turk J Gastroenterol. 20:41–47. 2009.PubMed/NCBI
28	Tang CH, Tan TW, Fu WM and Yang RS: Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis. 29:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
29	Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29:2513–2517. 2009.PubMed/NCBI
30	Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, et al: Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. Anticancer Res. 30:2693–2699. 2010.PubMed/NCBI
31	Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS and Moon H: Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol. 40:999–1013. 2010. View Article : Google Scholar : PubMed/NCBI
32	Ellington AA, Berhow MA and Singletary KW: Inhibition of Akt signaling and enhanced ERK1/2 activity are involved in induction of macroautophagy by triterpenoid B-group soyasaponins in colon cancer cells. Carcinogenesis. 27:298–306. 2006. View Article : Google Scholar : PubMed/NCBI
33	Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet RJ Jr, Mehrotra S, Morimiya A, Badve S and Nakshatri H: The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis. 26:900–907. 2005. View Article : Google Scholar : PubMed/NCBI
34	Wu K, Xu L, Zhang L, Lin Z and Hou J: High jagged1 expression predicts poor outcome in clear cell renal cell carcinoma. Jpn J Clin Oncol. 41:411–416. 2011. View Article : Google Scholar : PubMed/NCBI
35	de Seranno S and Meuwissen R: Progress and applications of mouse models for human lung cancer. Eur Respir J. 35:426–443. 2010. View Article : Google Scholar : PubMed/NCBI
36	Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG and Brown PH: Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 69:8853–8861. 2009. View Article : Google Scholar : PubMed/NCBI
37	Miao Y, Zhang Y, Wan H, Chen L and Wang F: GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells. Biomed Pharmacother. 64:583–588. 2010. View Article : Google Scholar : PubMed/NCBI